FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048401276> ?p ?o ?g. }

• W2048401276 endingPage "280" @default.
• W2048401276 startingPage "275" @default.
• W2048401276 abstract "Vasovagal syncope is a common problem associated with a poor quality of life, which improves when the frequency of syncope is reduced. Effective pharmacological therapies for vasovagal syncope have been elusive. Midodrine is a pro-drug whose primary metabolite is an alpha-1 adrenoreceptor agonist. A few studies have suggested that it may be beneficial in syncope, but all have had significant methodological limitations. A placebo-controlled clinical trial of midodrine for the prevention of vasovagal syncope is needed. The prevention of syncope trial IV (POST 4) is a multicenter, international, randomized, placebo-controlled study of midodrine in the prevention of vasovagal syncope. The primary end point is the time to first recurrence of syncope. Patients will be randomized 1:1 to receive midodrine 10–30 mg/day or matching placebo, and followed for 1 year. Secondary end points include syncope frequency, presyncope, and quality of life. Primary analysis will be performed with an intention-to-treat approach, with a secondary on-treatment analysis. A total sample size of 112, split equally between the two groups, achieves 85 % power to detect a 50 % relative risk reduction when the event rates are 55 and 27.5 % in the placebo and midodrine arms. Allowing for 20 % dropout, we propose to enroll 140 patients. POST 4 is registered with http://www.clinicaltrials.gov (NCT01456481). This study will be the first adequately powered trial to determine whether midodrine is effective in preventing vasovagal syncope. If it is effective, then midodrine may become the first-line pharmacological therapy for this condition." @default.
• W2048401276 created "2016-06-24" @default.
• W2048401276 creator A5063487192 @default.
• W2048401276 creator A5070734011 @default.
• W2048401276 creator A5075878586 @default.
• W2048401276 creator A5089433714 @default.
• W2048401276 date "2012-05-19" @default.
• W2048401276 modified "2023-09-25" @default.
• W2048401276 title "Rationale for the prevention of syncope trial IV: assessment of midodrine" @default.
• W2048401276 cites W102870620 @default.
• W2048401276 cites W103500556 @default.
• W2048401276 cites W1532520729 @default.
• W2048401276 cites W1971567816 @default.
• W2048401276 cites W1975703060 @default.
• W2048401276 cites W1988547111 @default.
• W2048401276 cites W2019374579 @default.
• W2048401276 cites W2031683977 @default.
• W2048401276 cites W2041450315 @default.
• W2048401276 cites W2042908317 @default.
• W2048401276 cites W2051501543 @default.
• W2048401276 cites W2058469386 @default.
• W2048401276 cites W2062592521 @default.
• W2048401276 cites W2075337959 @default.
• W2048401276 cites W2077642826 @default.
• W2048401276 cites W2078525134 @default.
• W2048401276 cites W2080738668 @default.
• W2048401276 cites W2087425057 @default.
• W2048401276 cites W2090492207 @default.
• W2048401276 cites W2103259378 @default.
• W2048401276 cites W2103669289 @default.
• W2048401276 cites W2105923514 @default.
• W2048401276 cites W2120769605 @default.
• W2048401276 cites W2124524808 @default.
• W2048401276 cites W2134598841 @default.
• W2048401276 cites W2140707532 @default.
• W2048401276 cites W2145507145 @default.
• W2048401276 cites W2147195656 @default.
• W2048401276 cites W2150381907 @default.
• W2048401276 cites W2159580288 @default.
• W2048401276 cites W2161321975 @default.
• W2048401276 cites W2167246752 @default.
• W2048401276 cites W2431445554 @default.
• W2048401276 doi "https://doi.org/10.1007/s10286-012-0167-5" @default.
• W2048401276 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3439533" @default.
• W2048401276 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22610268" @default.
• W2048401276 hasPublicationYear "2012" @default.
• W2048401276 type Work @default.
• W2048401276 sameAs 2048401276 @default.
• W2048401276 citedByCount "33" @default.
• W2048401276 countsByYear W20484012762012 @default.
• W2048401276 countsByYear W20484012762013 @default.
• W2048401276 countsByYear W20484012762014 @default.
• W2048401276 countsByYear W20484012762015 @default.
• W2048401276 countsByYear W20484012762016 @default.
• W2048401276 countsByYear W20484012762017 @default.
• W2048401276 countsByYear W20484012762018 @default.
• W2048401276 countsByYear W20484012762020 @default.
• W2048401276 countsByYear W20484012762021 @default.
• W2048401276 countsByYear W20484012762022 @default.
• W2048401276 crossrefType "journal-article" @default.
• W2048401276 hasAuthorship W2048401276A5063487192 @default.
• W2048401276 hasAuthorship W2048401276A5070734011 @default.
• W2048401276 hasAuthorship W2048401276A5075878586 @default.
• W2048401276 hasAuthorship W2048401276A5089433714 @default.
• W2048401276 hasBestOaLocation W20484012762 @default.
• W2048401276 hasConcept C126322002 @default.
• W2048401276 hasConcept C142724271 @default.
• W2048401276 hasConcept C164705383 @default.
• W2048401276 hasConcept C168563851 @default.
• W2048401276 hasConcept C203092338 @default.
• W2048401276 hasConcept C204787440 @default.
• W2048401276 hasConcept C27081682 @default.
• W2048401276 hasConcept C2777953023 @default.
• W2048401276 hasConcept C2778122182 @default.
• W2048401276 hasConcept C2780081974 @default.
• W2048401276 hasConcept C2780703726 @default.
• W2048401276 hasConcept C2781312747 @default.
• W2048401276 hasConcept C42219234 @default.
• W2048401276 hasConcept C71924100 @default.
• W2048401276 hasConcept C73787029 @default.
• W2048401276 hasConcept C84393581 @default.
• W2048401276 hasConceptScore W2048401276C126322002 @default.
• W2048401276 hasConceptScore W2048401276C142724271 @default.
• W2048401276 hasConceptScore W2048401276C164705383 @default.
• W2048401276 hasConceptScore W2048401276C168563851 @default.
• W2048401276 hasConceptScore W2048401276C203092338 @default.
• W2048401276 hasConceptScore W2048401276C204787440 @default.
• W2048401276 hasConceptScore W2048401276C27081682 @default.
• W2048401276 hasConceptScore W2048401276C2777953023 @default.
• W2048401276 hasConceptScore W2048401276C2778122182 @default.
• W2048401276 hasConceptScore W2048401276C2780081974 @default.
• W2048401276 hasConceptScore W2048401276C2780703726 @default.
• W2048401276 hasConceptScore W2048401276C2781312747 @default.
• W2048401276 hasConceptScore W2048401276C42219234 @default.
• W2048401276 hasConceptScore W2048401276C71924100 @default.
• W2048401276 hasConceptScore W2048401276C73787029 @default.
• W2048401276 hasConceptScore W2048401276C84393581 @default.
• W2048401276 hasIssue "6" @default.

• next